Effects of epigallocatechin gallate (EGCG) and Cissus Quadrangularis extract on adiposity, metabolic profiles, serum leptin, and resting metabolic rate
Phase 2
Completed
- Conditions
- Obesity and obesity related parametersobesity,Cissus Quadrangularis,EGCG,waist circumference,plasma triglyceride,blood pressure,kisspeptin
- Registration Number
- TCTR20200422001
- Lead Sponsor
- Faculty of Medicine Siriraj Hospital, Mahidol University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 45
Inclusion Criteria
Thai obese subjects, BMI ≥ 25 kg/m2 and age > 18 years, were recruited.
Exclusion Criteria
Subjects who were pregnant, lactating, menopause; had metabolic diseases (e.g. diabetes mellitus, hyper- or hypo-thyroidism, cushing syndrome), history of tea or caffeine hypersensitivity, a medical condition that causes weight gain known as secondary obesity (e.g. endocrine disorders, hypothalamic disorders, and some congenital conditions); used any forms of weight-reducing medications or any kinds of medications; and performed regular exercise (at least 30 min/session, 3 times per week48) were excluded.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method body weight and BMI 0, 4, and 8 weeks of treatments Kg and kg/m2,waist and hip circumferences 0, 4, and 8 weeks of treatments cm
- Secondary Outcome Measures
Name Time Method blood pressure 0, 4, and 8 weeks of treatments mmHg,Blood leptin, kisspeptin, and adiponectin levels 0, 4, and 8 weeks of treatments ng/ml,heart rate/heart rate variability (HRV) 0, 4, and 8 weeks of treatments beats/minute,fasting plasma insulin, triglyceride, total cholesterol, high-density lipoprotein (HDL) cholesterol, 0 and 8 weeks of treatments mg/dL,blood urea nitrogen (BUN), creatinine, and estimated glomerular filtration rate (eGFR) 0 and 8 weeks of treatments mg/dL,total bilirubin, direct bilirubin, aspartate aminotransferase, and alanine aminotransferase 0 and 8 weeks of treatments mg/d